Cognis Group Blog
  • Home
  • Foresight
  • Strategic Partnering
  • Contact
Cognis Group Blog
  • Home
  • Foresight
  • Strategic Partnering
  • Contact
Featured Technologies

Development of BBB-penetrating Peptide, DNP2, Based CTLA-4 Drug Candidate for Inducing Regulatory T Cells in Multiple Sclerosis

Opportunity ContactJames Noh, CEOSeoul, South Korea Hanyang University Website Pharmalicensing.com We identify a cell-permeable peptide, dNP2, which efficiently delivers proteins into mouse and human T cells, as well as various tissues. Introduction/BackgroundWe

November 15, 2020
Read more
Featured Technologies

Discovery of Therapeutic Target Genes for Individual Cancer Patients with a Genome-wide Quantitative Evaluation

Opportunity ContactJames Noh, CEOSeoul, South Korea Hanyang University Website Pharmalicensing.com A research team from Hanyang University in South Korea has developed a new technology for discovering therapeutic target genes for individual cancer patients with

November 14, 2020
Read more
Featured Technologies

BC201 – Treatment for Coronavirus Patients

BC201 is a combination of the peptide ingredient of VAL201 (a decapeptide currently in clinical testing for Oncology) with complementary active components to dampen this excessive immune response and consequently improve severe

November 2, 2020
Read more

2020 Cognis Group. All Rights Reserved.